Literature DB >> 7544248

A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.

R W Tindle1, S Croft, K Herd, K Malcolm, A F Geczy, T Stewart, G J Fernando.   

Abstract

TraT protein, known as ISCAR (= Immunostimulatory Carrier), is one of a family of integral membrane proteins (Imps) of Escherichia coli representing powerful carrier molecules which when injected into experimental animals generate substantial antibody and T proliferative responses to molecules conjugated to it. We extend these findings to show that ISCAR functions to stimulate Th1- and Th2-type responses, including specific cytotoxic T cells and tumour protection. We report here that by conjugating to ISCAR a 19mer peptide containing linear B epitopes, a T helper (Th) epitope, and a H-2b-restricted T cytotoxic (CTL) epitope of E7 protein of human papillomavirus type 16 (HPV16), and immunizing C57B1/6 (H-2b) mice, we elicited (i) specific IgG2a and IgG1 antibodies; (ii) IL-2 and IL-4 production by specifically recalled lymph node cells in vitro; (iii) cytotoxic T lymphocytes which specifically killed both E7 peptide-pulsed, and whole E7 gene-transfected tumour target cells; and (iv) in vivo protection against an E7 gene-transfected tumour cell inoculum. These findings have implications for the design of vaccines to stimulate immune responses to endogenously processed target antigens (e.g. tumour-associated antigens) without the unwanted side effects of oil-based adjuvants. In addition they support the case for a E7-targeted therapeutic vaccine for HPV-associated human cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544248      PMCID: PMC1553258          DOI: 10.1111/j.1365-2249.1995.tb08349.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

Review 1.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

2.  Algammulin (gamma inulin/alum hybrid adjuvant) has greater adjuvanticity than alum for hepatitis B surface antigen in mice.

Authors:  P D Cooper; R Turner; J McGovern
Journal:  Immunol Lett       Date:  1991-02       Impact factor: 3.685

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  A plasmid-encoded outer membrane protein, TraT, enhances resistance of Escherichia coli to phagocytosis.

Authors:  M E Agüero; L Aron; A G DeLuca; K N Timmis; F C Cabello
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

5.  Biology and biochemistry of papillomaviruses.

Authors:  H Pfister
Journal:  Rev Physiol Biochem Pharmacol       Date:  1984       Impact factor: 5.545

6.  Immunogenicity of a synthetic HBsAg peptide: enhancement by conjugation to a fatty acid carrier.

Authors:  T P Hopp
Journal:  Mol Immunol       Date:  1984-01       Impact factor: 4.407

7.  The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein.

Authors:  D Smotkin; F O Wettstein
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes.

Authors:  R W Tindle; G J Fernando; J C Sterling; I H Frazer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

9.  Adoptive immunotherapy of newly induced murine sarcomas.

Authors:  S Y Shu; S A Rosenberg
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

10.  Adjuvant effect of bacterial LPS and/or alum precipitation in responses to polysaccharide and protein antigens.

Authors:  I J Seppälä; O Mäkelä
Journal:  Immunology       Date:  1984-12       Impact factor: 7.397

View more
  10 in total

1.  New age adjuvants and delivery systems for subunit vaccines.

Authors:  S Kurella; M Manocha; L Sabhnani; B Thomas; D N Rao
Journal:  Indian J Clin Biochem       Date:  2000-08

2.  Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins.

Authors:  Guglielmo Lucchese; Giovanni Capone; Darja Kanduc
Journal:  Schizophr Bull       Date:  2013-01-31       Impact factor: 9.306

3.  Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.

Authors:  A Lamikanra; Z K Pan; S N Isaacs; T C Wu; Y Paterson
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles.

Authors:  T Doan; K Herd; M Street; G Bryson; G Fernando; P Lambert; R Tindle
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis.

Authors:  Wen-Fang Cheng; Chien-Fu Hung; Chi-An Chen; Chien-Nan Lee; Yi-Ning Su; Chee-Yin Chai; David A K Boyd; Chang-Yao Hsieh; T-C Wu
Journal:  Vaccine       Date:  2004-11-24       Impact factor: 3.641

6.  Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

Authors:  Ryan A Wilcox; Dallas B Flies; Gefeng Zhu; Aaron J Johnson; Koji Tamada; Andrei I Chapoval; Scott E Strome; Larry R Pease; Lieping Chen
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

7.  Inhibition of apoptosis, activation of NKT cell and upregulation of CD40 and CD40L mediated by M. leprae antigen(s) combined with Murabutide and Trat peptide in leprosy patients.

Authors:  Vineeta Chattree; Neena Khanna; Vandana Bisht; D N Rao
Journal:  Mol Cell Biochem       Date:  2007-11-16       Impact factor: 3.396

8.  Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses.

Authors:  Wenyi Gu; Melanie Cochrane; Graham R Leggatt; Elizabeth Payne; Allison Choyce; Fang Zhou; Robert Tindle; Nigel A J McMillan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-04       Impact factor: 11.205

9.  Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.

Authors:  Michael D Street; Tracy Doan; Karen A Herd; Robert W Tindle
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

10.  HPV16 E7 expression in skin induces TSLP secretion, type 2 ILC infiltration and atopic dermatitis-like lesions.

Authors:  Anne-Sophie Bergot; Nastasia Monnet; Son Le Tran; Deepak Mittal; Jane Al-Kouba; Raymond J Steptoe; Michele A Grimbaldeston; Ian H Frazer; James W Wells
Journal:  Immunol Cell Biol       Date:  2015-01-20       Impact factor: 5.126

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.